Community Collaboration to Combat COVID-19 (C-FORWARD)
Primary Purpose
Coronavirus Infection
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fixed site standard of care testing
Community-based, mobile van testing
Self-collected, home-based testing
Sponsored by
About this trial
This is an interventional screening trial for Coronavirus Infection
Eligibility Criteria
Inclusion Criteria for households
- Selected address within Baltimore City
- At least one member of the household >18 years of age who speaks English and/or Spanish
- At least one member of the household provides informed consent
- At least one member of the household psychologically fit to complete survey
Inclusion Criteria for Individuals
- Reports primary residence within the sampled household
- Provides informed consent
- For children (12 years of age or older), with child assent.
Exclusion Criteria for households:
- Adult member of the household is under the influence of illicit substances, in the opinion of the phone interviewer
- Residents of nursing homes, half-ways houses or shelters
- Psychologically unfit to complete the survey
- Not a selected household address
Exclusion criteria for individuals
1. Person providing informed consent is under the influence of illicit substances
Sites / Locations
- 2212 McElderry Street
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Fixed site SOC testing
Community-based testing
Self-collected testing
Arm Description
Fixed site Standard of Care (SOC) testing
Community-based, mobile van testing
Self-collected, home-based testing
Outcomes
Primary Outcome Measures
Uptake of SARS-CoV-2 testing as assessed by proportion of participants who complete testing
Uptake of SARS CoV-2 testing will be assessed by proportion of participants who are randomized and complete SARS CoV-2 testing.
Secondary Outcome Measures
Receipt of SARS-CoV-2 testing results
Proportion of those who complete a survey who agree to be randomized to a SARS-CoV-2 testing modality.
Uptake of SARS CoV-2 testing as assessed by proportion of participants who complete testing
Uptake of SARS CoV-2 testing will be assessed by proportion of participants who are randomized and complete SARS CoV-2 testing.
Time to completion of SARS CoV-2 testing
Time (In days) to completion of SARS CoV-2 testing from randomization.
Time from SARS CoV-2 testing to receipt of results
Time (in days) from SARS CoV-2 testing completion to the receipt of results by the participant.
Full Information
NCT ID
NCT04673292
First Posted
December 16, 2020
Last Updated
August 10, 2023
Sponsor
Johns Hopkins University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
1. Study Identification
Unique Protocol Identification Number
NCT04673292
Brief Title
Community Collaboration to Combat COVID-19 (C-FORWARD)
Official Title
Community Collaboration to Combat COVID-19
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 8, 2021 (Actual)
Primary Completion Date
June 9, 2023 (Actual)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is randomized trial where households will be randomized to identify the optimal SARS-CoV-2 (COVID-19) testing modality in a population-representative sample of households in Baltimore City, Maryland. 1,386 households in Baltimore City will be randomized 1:1:1 to one of three testing modalities: 1) fixed-site standard of care testing; 2) community-based mobile van testing; or 3) self-collected home, based testing.
Detailed Description
The target population will include English- and Spanish-speaking families residing in Baltimore City households (N=238,427). The sample size goal is 1,386 households (0.44% of households) or 3,000 individual household members. Households will be sampled using a multi-stage approach with 1) selection of 105 of 653 census block groups (CBGs) with probabilities proportional to the estimated number of occupied households selected from 9 strata of CBGs defined by socioeconomic status and race/ethnicity with over-sampling of CBGs with harder-to-reach populations (e.g., Latinos/x, low-income whites); 2) selection of residential addresses within each of the strata via non-linear optimization; and finally, 3) screening of individuals selected for eligibility (e.g., household occupied vs. not, English/Spanish speaking).
After completion of brief surveys, individuals will be asked to enroll other willing household members. One adult member of the household will be randomized 1:1:1 using a stratified, blocked approach with varying block sizes of 3, to one of three testing modalities: 1) fixed site standard of care testing; 2) community-based mobile van testing; or 3) self-collected home, based testing. Randomization will be stratified by geography (n=12 zones) and race/ethnicity (non-hispanic white/other, non-hispanic black and hispanic/latinx).
Arm 1 includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system.
Arm 2 includes a convenient, accessible mobile van option which will be located in the center of each of 12 geographic zones.
Arm 3 includes a home-based testing kit which will be delivered by courier service.
Outcomes related to testing will be measured within 30 days of the initial randomization. Participants will be followed with weekly symptom pulses and monthly follow-up visits to ascertain subsequent testing need/COVID-19 symptoms. Testing during follow-up will be on-demand and participants can use either the fixed site or the home-based testing kits. The investigators will measure the impact of the time to receipt of SARS CoV-2 testing results.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronavirus Infection
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Each household will be randomized to one of three arms in the study: Fixed site SOC testing (Arm 1), community-based, mobile van testing (Arm 2), or self-collected, home-based testing (Arm 3).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fixed site SOC testing
Arm Type
Experimental
Arm Description
Fixed site Standard of Care (SOC) testing
Arm Title
Community-based testing
Arm Type
Experimental
Arm Description
Community-based, mobile van testing
Arm Title
Self-collected testing
Arm Type
Experimental
Arm Description
Self-collected, home-based testing
Intervention Type
Behavioral
Intervention Name(s)
Fixed site standard of care testing
Intervention Description
This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
Intervention Type
Behavioral
Intervention Name(s)
Community-based, mobile van testing
Intervention Description
This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
Intervention Type
Behavioral
Intervention Name(s)
Self-collected, home-based testing
Intervention Description
Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
Primary Outcome Measure Information:
Title
Uptake of SARS-CoV-2 testing as assessed by proportion of participants who complete testing
Description
Uptake of SARS CoV-2 testing will be assessed by proportion of participants who are randomized and complete SARS CoV-2 testing.
Time Frame
Measured within 30 days of randomization/consent
Secondary Outcome Measure Information:
Title
Receipt of SARS-CoV-2 testing results
Description
Proportion of those who complete a survey who agree to be randomized to a SARS-CoV-2 testing modality.
Time Frame
Measured from baseline survey completion to enrollment within 30 days of completion of baseline survey
Title
Uptake of SARS CoV-2 testing as assessed by proportion of participants who complete testing
Description
Uptake of SARS CoV-2 testing will be assessed by proportion of participants who are randomized and complete SARS CoV-2 testing.
Time Frame
Measured from randomization to testing completion (within 30 days of randomization)
Title
Time to completion of SARS CoV-2 testing
Description
Time (In days) to completion of SARS CoV-2 testing from randomization.
Time Frame
Measured from randomization to testing completion (Within 20 days of randomization)
Title
Time from SARS CoV-2 testing to receipt of results
Description
Time (in days) from SARS CoV-2 testing completion to the receipt of results by the participant.
Time Frame
Measured from testing completion to receipt of results (within 10 days of testing)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria for households
Selected address within Baltimore City
At least one member of the household >18 years of age who speaks English and/or Spanish
At least one member of the household provides informed consent
At least one member of the household psychologically fit to complete survey
Inclusion Criteria for Individuals
Reports primary residence within the sampled household
Provides informed consent
For children (12 years of age or older), with child assent.
Exclusion Criteria for households:
Adult member of the household is under the influence of illicit substances, in the opinion of the phone interviewer
Residents of nursing homes, half-ways houses or shelters
Psychologically unfit to complete the survey
Not a selected household address
Exclusion criteria for individuals
1. Person providing informed consent is under the influence of illicit substances
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jason E Farley, PhD, MPH, NP
Organizational Affiliation
Johns Hopkins University School of Nursing
Official's Role
Principal Investigator
Facility Information:
Facility Name
2212 McElderry Street
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Community Collaboration to Combat COVID-19 (C-FORWARD)
We'll reach out to this number within 24 hrs